These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 24370700)

  • 1. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
    Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
    Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
    Chiu WH; Depboylu C; Hermanns G; Maurer L; Windolph A; Oertel WH; Ries V; Höglinger GU
    Neuropharmacology; 2015 Aug; 95():367-76. PubMed ID: 25839898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
    Lindgren HS; Ohlin KE; Cenci MA
    Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
    Kemmerer ES; Desmond TJ; Albin RL; Kilbourn MR; Frey KA
    Exp Neurol; 2003 Sep; 183(1):81-6. PubMed ID: 12957491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
    Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
    Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
    Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
    El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
    Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
    Fang C; Yin J; Xu Z; Wang Y; Xu H; Zhou H; Gao C
    Cell Biochem Biophys; 2011 Jan; 59(1):49-56. PubMed ID: 20714825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats.
    Périer C; Marin C; Jimenez A; Bonastre M; Tolosa E; Hirsch EC
    J Neurochem; 2003 Sep; 86(6):1328-37. PubMed ID: 12950442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
    Marin C; Aguilar E; Mengod G; Cortés R; Rodríguez-Oroz MC; Obeso JA
    Neurobiol Dis; 2008 Dec; 32(3):340-8. PubMed ID: 18722529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
    Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
    Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
    Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
    Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.